GW-5282 / Dizal Pharmaceutical - LARVOL DELTA

Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3) (clinicaltrials.gov) - P1/2 | N=165 | Recruiting | Sponsor: Dizal Pharmaceuticals | Not yet recruiting ➔ Recruiting

Enrollment open • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma

Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3) (clinicaltrials.gov) - P1/2 | N=165 | Not yet recruiting | Sponsor: Dizal Pharmaceuticals

New P1/2 trial • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma

A Phase 1/2 Study of GW5282 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=203 | Recruiting | Sponsor: Dizal Pharmaceuticals | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor

A Phase 1/2 Study of GW5282 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=203 | Not yet recruiting | Sponsor: Dizal Pharmaceuticals

New P1/2 trial • Oncology • Solid Tumor